EndometriosisNCT07693283
Expression of Target in Endometriotic Lesions
An observational study of Endometriosis, run by Beijing Tsinghua Chang Gung Hospital at 1 site in China.
Trial summary
Endometriosis is a common gynecological disorder associated with chronic pelvic pain and infertility, which affects women of reproductive age worldwide. This study aims to investigate the expression patterns of specific molecules in tissue specimens obtained from patients with endometriosis. Read more about this study
- Who is it for?
- Ages 18 to 50 years, women only
- Conditions the study is for
- Endometriosis
- What is being tested?
- Retrospective molecular expression analysis in endometriosis tissue specimens
- How many people
- 40 participants
- Where
- 1 siteChina
- Study dates
- 13 Apr 2026to 12 Feb 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- Women only
- No healthy volunteers
- Adult
Study population: Female reproductive-aged patients with histopathologically confirmed endometriosis . Patients with malignant gynecological diseases are excluded.
Who may be able to join
- Pathologically confirmed endometriosis via laparoscopy and histopathological examination
- Complete clinical and pathological data available
Who cannot join
- History of any malignant tumor
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Beijing Tsinghua Changgung Hospital
Beijing, Beijing Municipality, 102218
Lei Zhang, 8618601130459, 18601130459@163.com
About this study
Official title: To Investigate the Expression of Target in Endometriotic Lesions
Endometriosis is a common gynecological disorder associated with chronic pelvic pain and infertility, which affects women of reproductive age worldwide. This study aims to investigate the expression patterns of specific molecules in tissue specimens obtained from patients with endometriosis. The investigators will compare the expression levels of these molecules between endometriotic lesions and normal tissue. The primary objective of this study is to elucidate the potential roles of these molecules in the pathogenesis of endometriosis.
- Conditions
- Endometriosis
- Being tested
- Retrospective molecular expression analysis in endometriosis tissue specimens
- Medical subject headings
- Endometriosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Retrospective molecular expression analysis in endometriosis tissue specimensOther
This study involves no prospective interventional measures for participants.
| Study group | Role | What they receive |
|---|---|---|
| patients with endometriosis | Not described Receives: Other: Retrospective molecular expression analysis in endometriosis tissue specimens |
What is being measured
The primary outcome is the main question the study is designed to answer.
Expression levels of molecular in endometriotic lesions and adjacent normal tissue
Standardized pathological histology assessment method
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jul 2026
- Study start13 Apr 2026
- Primary completion30 Sep 2026 (estimated)
- Study completion12 Feb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for EndometriosisStudies of the same condition, open and under way.
- More trials run by Beijing Tsinghua Chang Gung HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Beijing Tsinghua Chang Gung Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Lei Zhang, Beijing Tsinghua Chang Gung Hospital
- Investigators
- Lei Zhang, Principal investigator, Beijing Tsinghua Changgeng Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07693283
- Sponsor's protocol ID
- 26154-4-01
- Status last verified
- Apr 2026
- First submitted
- 26 Mar 2026
- Last updated
- 9 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- To Investigate the Expression of Target in Endometriotic Lesions
- ClinicalTrials.gov ID
- NCT07693283
- Acronym / sponsor ID
- 26154-4-01
- Conditions
- Endometriosis
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Beijing Tsinghua Chang Gung HospitalUniversity, hospital or other
- Study start
- 13 Apr 2026 (actual)
- Primary completion
- 30 Sep 2026 (estimated)
- Study completion
- 12 Feb 2027 (estimated)
- First posted
- 9 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Endometriosis is a common gynecological disorder associated with chronic pelvic pain and infertility, which affects women of reproductive age worldwide. This study aims to investigate the expression patterns of specific molecules in tissue specimens obtained from patients with endometriosis. The investigators will compare the expression levels of these molecules between endometriotic lesions and normal tissue. The primary objective of this study is to elucidate the potential roles of these molecules in the pathogenesis of endometriosis.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| patients with endometriosis | – | Other: Retrospective molecular expression analysis in endometriosis tissue specimens |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- Female reproductive-aged patients with histopathologically confirmed endometriosis . Patients with malignant gynecological diseases are excluded.
Key inclusion criteria (2 listed)
- Pathologically confirmed endometriosis via laparoscopy and histopathological examination
- Complete clinical and pathological data available
Key exclusion criteria (1 listed)
- History of any malignant tumor
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Retrospective molecular expression analysis in endometriosis tissue specimensThis study involves no prospective interventional measures for participants. | Other | patients with endometriosis |
Primary outcome
Expression levels of molecular in endometriotic lesions and adjacent normal tissue
Time frame: 6 months
Standardized pathological histology assessment method
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Endometriosis
Not yet recruiting
Prevalence of Small Intestinal Bacterial Overgrowth (SIBO) in Women With Endometriosis
SIBO, Endometriosis
Recruiting
Endometriosis Transcriptomic Cell Atlas
Endometriosis, Infertility
Not yet recruiting
Psychotherapy in Patients With Endometriosis: Cognitive Behavioral Therapy Versus Acceptance and Commitment Therapy
Endometriosis, Adenomyosis
Not yet recruitingObservational study
Impact of a Diagnosis or Lack of a Diagnosis of Endometriosis Via a Saliva Test on Pain Catastrophizing, Quality of Life, Symptoms of Anxiety and Depression, and Treatment Adherence
Endometriosis
Not yet recruitingPhase 2
PRECISION-E2: Teverelix in Women With Endometriosis - Pharmacodynamics, Safety and Precision Medicine Correlates
Endometriosis Pelvic, Endometriosis Ovaries
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Lei Zhang principal investigator
Beijing Tsinghua Changgeng Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Endometriosis, run by Beijing Tsinghua Chang Gung Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 9 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Lei Zhang (+86 186 0113 0459, 461458953@qq.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Expression levels of molecular in endometriotic lesions and adjacent normal tissue (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jul 2026.